Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.

Abstract: Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders. The compounds can be represented by the formula: ##STR1## where X is O, S or NR.sup.15.

Abstract: A novel human corticotropin releasing hormone (CRH) receptor which is a splice variant of the human CRH.sub.2 receptor subfamily and is designated human CRHR2.gamma.. Fragments of CRHR2.gamma.. Nucleic acid molecules which encode CRHR2.gamma. and fragments, expression vectors comprising the nucleic acid molecules, and host cells containing the expression vectors. Antibodies and antibody fragments capable of binding the novel receptor. Nucleic acid molecules capable of hybridizing with the above nucleic acid molecules. Use of the novel receptor and receptor fragments, antibodies and antibody fragments in testing compounds for CRH antagonist activity and in treating diseases.

Abstract: Biologically active analogs of human IL2, which differ from natural IL2 by the substitution of amino acid residues to form N-linked glycosylation sites in the molecule, are prepared by recombinant DNA techniques. Such analogs of IL2 are N-linked glycosylated when expressed in eukaryotic cells. Natural IL2 is not N-linked glycosylated.

Abstract: This invention is a process for purifying nucleoside-5'-diphosphates containing substituents other than primary amines (hereinafter designated as NDPs) from complex mixtures by contacting the aqueous solution mixture with a strongly basic ion exchange resin in the chloride form, eluting certain absorbed impurities with an alkali metal salt solution, converting the column to the hydroxide form by contacting the resin with an alkali metal hydroxide solution such that the effluent becomes basic, and eluting absorbed NDP with a weakly acidic alkali metal salt solution such that solutions of highly pure NDP are obtained in basic effluent fractions. The new process is particularly valuable for purification of NDPs directly from chemical synthesis reaction media.